Cargando…

Perceptions of patients with rheumatic diseases on the impact on daily life and satisfaction with their medications: RHEU-LIFE, a survey to patients treated with subcutaneous biological products

OBJECTIVE: The aim of this study was to explore perceptions of patients with rheumatic diseases treated with subcutaneous (SC) biological drugs on the impact on daily life and satisfaction with current therapy, including preferred attributes. METHODS: A survey was developed ad hoc by four rheumatolo...

Descripción completa

Detalles Bibliográficos
Autores principales: González, Carlos M, Carmona, Loreto, de Toro, Javier, Batlle-Gualda, Enrique, Torralba, Antonio I, Arteaga, María J, Cea-Calvo, Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5530861/
https://www.ncbi.nlm.nih.gov/pubmed/28790806
http://dx.doi.org/10.2147/PPA.S137052
_version_ 1783253314047049728
author González, Carlos M
Carmona, Loreto
de Toro, Javier
Batlle-Gualda, Enrique
Torralba, Antonio I
Arteaga, María J
Cea-Calvo, Luis
author_facet González, Carlos M
Carmona, Loreto
de Toro, Javier
Batlle-Gualda, Enrique
Torralba, Antonio I
Arteaga, María J
Cea-Calvo, Luis
author_sort González, Carlos M
collection PubMed
description OBJECTIVE: The aim of this study was to explore perceptions of patients with rheumatic diseases treated with subcutaneous (SC) biological drugs on the impact on daily life and satisfaction with current therapy, including preferred attributes. METHODS: A survey was developed ad hoc by four rheumatologists and three patients, including Likert questions on the impact of disease and treatment on daily life and preferred attributes of treatment. Rheumatologists from 50 participating centers were instructed to handout the survey to 20 consecutive patients with rheumatoid arthritis (RA), axial spondyloarthritis (ax-SpA), or psoriatic arthritis (PsA) receiving SC biological drugs. Patients responded to the survey at home and sent it to a central facility by prepaid mail. RESULTS: A total of 592 patients returned the survey (response rate: 59.2%), 51.4% of whom had RA, 23.8% had ax-SpA, and 19.6% had PsA. Patients reported moderate-to-severe impact of their disease on their quality of life (QoL) (51.9%), work/daily activities (49.2%), emotional well-being (41.0%), personal relationships (26.0%), and close relatives’ life (32.3%); 30%–50% patients reported seldom/never being inquired about these aspects by their rheumatologists. Treatment attributes ranked as most important were the normalization of QoL (43.6%) and the relief from symptoms (35.2%). The satisfaction with their current antirheumatic therapy was high (>80% were “satisfied” or “very satisfied”), despite moderate/severe impact of disease. CONCLUSION: Patients with rheumatic diseases on SC biological therapy perceive a high disease impact on different aspects of daily life, despite being highly satisfied with their treatment; the perception is that physicians do not frequently address personal problems. Normalization of QoL is the most important attribute of therapies to patients.
format Online
Article
Text
id pubmed-5530861
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-55308612017-08-08 Perceptions of patients with rheumatic diseases on the impact on daily life and satisfaction with their medications: RHEU-LIFE, a survey to patients treated with subcutaneous biological products González, Carlos M Carmona, Loreto de Toro, Javier Batlle-Gualda, Enrique Torralba, Antonio I Arteaga, María J Cea-Calvo, Luis Patient Prefer Adherence Original Research OBJECTIVE: The aim of this study was to explore perceptions of patients with rheumatic diseases treated with subcutaneous (SC) biological drugs on the impact on daily life and satisfaction with current therapy, including preferred attributes. METHODS: A survey was developed ad hoc by four rheumatologists and three patients, including Likert questions on the impact of disease and treatment on daily life and preferred attributes of treatment. Rheumatologists from 50 participating centers were instructed to handout the survey to 20 consecutive patients with rheumatoid arthritis (RA), axial spondyloarthritis (ax-SpA), or psoriatic arthritis (PsA) receiving SC biological drugs. Patients responded to the survey at home and sent it to a central facility by prepaid mail. RESULTS: A total of 592 patients returned the survey (response rate: 59.2%), 51.4% of whom had RA, 23.8% had ax-SpA, and 19.6% had PsA. Patients reported moderate-to-severe impact of their disease on their quality of life (QoL) (51.9%), work/daily activities (49.2%), emotional well-being (41.0%), personal relationships (26.0%), and close relatives’ life (32.3%); 30%–50% patients reported seldom/never being inquired about these aspects by their rheumatologists. Treatment attributes ranked as most important were the normalization of QoL (43.6%) and the relief from symptoms (35.2%). The satisfaction with their current antirheumatic therapy was high (>80% were “satisfied” or “very satisfied”), despite moderate/severe impact of disease. CONCLUSION: Patients with rheumatic diseases on SC biological therapy perceive a high disease impact on different aspects of daily life, despite being highly satisfied with their treatment; the perception is that physicians do not frequently address personal problems. Normalization of QoL is the most important attribute of therapies to patients. Dove Medical Press 2017-07-19 /pmc/articles/PMC5530861/ /pubmed/28790806 http://dx.doi.org/10.2147/PPA.S137052 Text en © 2017 González et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
González, Carlos M
Carmona, Loreto
de Toro, Javier
Batlle-Gualda, Enrique
Torralba, Antonio I
Arteaga, María J
Cea-Calvo, Luis
Perceptions of patients with rheumatic diseases on the impact on daily life and satisfaction with their medications: RHEU-LIFE, a survey to patients treated with subcutaneous biological products
title Perceptions of patients with rheumatic diseases on the impact on daily life and satisfaction with their medications: RHEU-LIFE, a survey to patients treated with subcutaneous biological products
title_full Perceptions of patients with rheumatic diseases on the impact on daily life and satisfaction with their medications: RHEU-LIFE, a survey to patients treated with subcutaneous biological products
title_fullStr Perceptions of patients with rheumatic diseases on the impact on daily life and satisfaction with their medications: RHEU-LIFE, a survey to patients treated with subcutaneous biological products
title_full_unstemmed Perceptions of patients with rheumatic diseases on the impact on daily life and satisfaction with their medications: RHEU-LIFE, a survey to patients treated with subcutaneous biological products
title_short Perceptions of patients with rheumatic diseases on the impact on daily life and satisfaction with their medications: RHEU-LIFE, a survey to patients treated with subcutaneous biological products
title_sort perceptions of patients with rheumatic diseases on the impact on daily life and satisfaction with their medications: rheu-life, a survey to patients treated with subcutaneous biological products
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5530861/
https://www.ncbi.nlm.nih.gov/pubmed/28790806
http://dx.doi.org/10.2147/PPA.S137052
work_keys_str_mv AT gonzalezcarlosm perceptionsofpatientswithrheumaticdiseasesontheimpactondailylifeandsatisfactionwiththeirmedicationsrheulifeasurveytopatientstreatedwithsubcutaneousbiologicalproducts
AT carmonaloreto perceptionsofpatientswithrheumaticdiseasesontheimpactondailylifeandsatisfactionwiththeirmedicationsrheulifeasurveytopatientstreatedwithsubcutaneousbiologicalproducts
AT detorojavier perceptionsofpatientswithrheumaticdiseasesontheimpactondailylifeandsatisfactionwiththeirmedicationsrheulifeasurveytopatientstreatedwithsubcutaneousbiologicalproducts
AT batllegualdaenrique perceptionsofpatientswithrheumaticdiseasesontheimpactondailylifeandsatisfactionwiththeirmedicationsrheulifeasurveytopatientstreatedwithsubcutaneousbiologicalproducts
AT torralbaantonioi perceptionsofpatientswithrheumaticdiseasesontheimpactondailylifeandsatisfactionwiththeirmedicationsrheulifeasurveytopatientstreatedwithsubcutaneousbiologicalproducts
AT arteagamariaj perceptionsofpatientswithrheumaticdiseasesontheimpactondailylifeandsatisfactionwiththeirmedicationsrheulifeasurveytopatientstreatedwithsubcutaneousbiologicalproducts
AT ceacalvoluis perceptionsofpatientswithrheumaticdiseasesontheimpactondailylifeandsatisfactionwiththeirmedicationsrheulifeasurveytopatientstreatedwithsubcutaneousbiologicalproducts